Drug · CHEMBL196
ASCORBIC ACID
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. ASCORBIC ACID. Drugs and targets, record CHEMBL196. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL196
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Brand names
Ascor, Ascorbic acid component of moviprep, Ascorbic acid component of plenvu, Ascorbic acid component of vitaped, Ascorbicap, Ascur, Bassett's, Haliborange, Redoxon, Redoxon c, Redoxon chew-c, Redoxon slow release, Top c, Vital life
- ChEMBL
- Other names
3-keto-l-gulofuranolactone, Acide ascorbique, Acido ascorbico, Acidum ascorbicum, Ascoltin, Ascorbate, Ascorbic acid (vit c), Ascorbic acid, l-, Ascorbicum acidum, E-300, E300, FEMA NO. 2109, INS NO.300, INS-300, L-ascorbate, L-ascorbic acid, NSC-218455, NSC-33832, Vitamin c (as ascorbic acid)
- ChEMBL
- Open Targets' highest stage
- Approval, for 7 of its 142 diseases, from ATC, ClinicalTrials.gov, DailyMed and TTD
- Open Targets
Targets0
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
None in this release.
Diseases142
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 142Source Open Targets
See all 142 diseasesTrials264
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 33 more rest on that reading alone and are shown because the trials' posted result groups or NLM's indexing of their papers name the drug. 148 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT00135707 | Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS) | Phase 3 | 10,154 | 2018-11-20 | vitamin C | Open Targets' reading, confirmed by NLM's indexing of its papers | ClinicalTrials.gov |
| NCT02956057 | Polyethylene Glycol Versus Low Volume Solutions Prior to Colonoscopy | Phase 4 | 1,044 | 2020-10-28 | polyethylene glycol / ascorbic acid | A combination that names it | ClinicalTrials.gov |
| NCT04328961 | Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP) | Phase 2/3 | 943 | 2021-12-16 | ascorbic acid | Its name | ClinicalTrials.gov |
| NCT03509350 | Vitamin C, Thiamine, and Steroids in Sepsis | Phase 3 | 501 | 2020-09-18 | vitamin C | Open Targets' reading, confirmed by NLM's indexing of its papers | ClinicalTrials.gov |
| NCT00953212 | Prophylaxis to Reduce Postoperative Atrial Fibrillation in Cardiac Surgery | Phase 3 | 304 | 2018-03-29 | ascorbic acid | Its name | ClinicalTrials.gov |
| NCT03389555 | Ascorbic Acid, Corticosteroids, and Thiamine in Sepsis (ACTS) Trial | Phase 2/3 | 205 | 2021-01-29 | ascorbic acid | Its name | ClinicalTrials.gov |
| NCT02106975 | Vitamin C Infusion for Treatment in Sepsis Induced Acute Lung Injury | Phase 2 | 170 | 2019-10-15 | ascorbic acid | Its name | ClinicalTrials.gov |
| NCT01732692 | Evaluation of the Efficacy, Safety and Tolerance of Experimental Morning-only MOVIPREP® Bowel Preparation in Comparison With Split-dose With Nocturnal Pause MOVIPREP® Bowel Preparation | Phase 3 | 140 | 2014-05-15 | moviprep | Open Targets' reading, confirmed by the trial's result groups | ClinicalTrials.gov |
| NCT03422159 | Metabolic Resuscitation Using Ascorbic Acid, Thiamine, and Glucocorticoids in Sepsis. | Phase 2 | 140 | 2021-09-21 | ascorbic acid | Its name | ClinicalTrials.gov |
| NCT02216812 | Does Vitamin C Reduce Finger Stiffness After Distal Radius Fractures? | 134 | 2018-09-17 | ascorbic acid | Its name | ClinicalTrials.gov |
1 to 10 of 264
See all 264 trialsComparisons in its trials72
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Ascorbic Acid vs Hydroxychloroquine: deaths from any cause | 0 of 422 | 0 of 407 | 829 | NCT04328961 | Trial comparisons |
| Ascorbic Acid vs Hydroxychloroquine: serious adverse events | 2 of 422 | 2 of 407 | 829 | NCT04328961 | Trial comparisons |
| Ascorbic Acid vs Hydroxychloroquine: Rate of Participant-reported Adverse Events | 46 of 336 | 66 of 353 | 689 | NCT04328961 | Trial comparisons |
| Ascorbic Acid vs Hydroxychloroquine: Number of Participants Who Had Polymerase Chain Reaction (PCR) Confirmed SARS-CoV-2 Infection | 45 of 336 | 53 of 353 | 689 | NCT04328961 | Trial comparisons |
| Ascorbic Acid vs Hydroxychloroquine: Number of Participants Who Had COVID-19 Disease | 26 of 336 | 37 of 353 | 689 | NCT04328961 | Trial comparisons |
| Ascorbic Acid vs Hydroxychloroquine: The Number of Participants Who Had Polymerase Chain Reaction (PCR) Confirmed SARS-CoV-2 Infection | 48 of 336 | 58 of 353 | 689 | NCT04328961 | Trial comparisons |
| Vitamin C, Vitamin B1, Corticosteroids vs Placebo: Intensive Care Unit (ICU) Mortality | 23 of 101 | 20 of 99 | 200 | NCT03389555 | Trial comparisons |
| Vitamin C, Vitamin B1, Corticosteroids vs Placebo: 30-day Mortality | 35 of 101 | 29 of 99 | 200 | NCT03389555 | Trial comparisons |
| Vitamin C, Vitamin B1, Corticosteroids vs Placebo: Renal Failure | 32 of 101 | 27 of 99 | 200 | NCT03389555 | Trial comparisons |
| Vitamin C, Vitamin B1, Corticosteroids vs Placebo: Hospital Mortality | 28 of 101 | 23 of 99 | 200 | NCT03389555 | Trial comparisons |
1 to 10 of 72
See all 72 comparisons in its trialsPapers from its trials157
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL196
GET https://conductscience.org/api/drugs/v1/CHEMBL196/diseases?page=2